Ahn H, Lee SY, Jung WJ, Lee KH. Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: A case report . World J Stem Cells 2021; 13(8): 1151-1159 [PMID: 34567432 DOI: 10.4252/wjsc.v13.i8.1151]
Corresponding Author of This Article
Kye-Ho Lee, PhD, bio Beauty&Health Company (bBHC) - Stem Cell Treatment & Research Institute (STRI), 72 UN village-gil Yongsan-gu, Seoul 04420, South Korea. khlee@stc365.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Aug 26, 2021; 13(8): 1151-1159 Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.1151
Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: A case report
Hyunjun Ahn, Sang Yeon Lee, Won Ju Jung, Kye-Ho Lee
Hyunjun Ahn, Sang Yeon Lee, Kye-Ho Lee, bio Beauty&Health Company (bBHC)-Stem Cell Treatment & Research Institute (STRI), Seoul 04420, South Korea
Won Ju Jung, 97.7 Beauty&Health (B&H) Clinics, Seoul 04420, South Korea
Author contributions: Ahn H, Lee SY, Jung WJ, and Lee KH designed the reports; Ahn H and Jung WJ collected the patients’ clinical data; Ahn H, Lee SY, and Jung WJ analyzed the data; Ahn H wrote the manuscript; Lee KH provided professional advice and revised the manuscript; all authors issued final approval for the version to be submitted.
Informed consent statement: The patients involved in this study gave their written informed consent authorizing disclosure of protected health information.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kye-Ho Lee, PhD, bio Beauty&Health Company (bBHC) - Stem Cell Treatment & Research Institute (STRI), 72 UN village-gil Yongsan-gu, Seoul 04420, South Korea. khlee@stc365.com
Received: May 21, 2021 Peer-review started: May 21, 2021 First decision: June 16, 2021 Revised: June 23, 2021 Accepted: August 6, 2021 Article in press: August 6, 2021 Published online: August 26, 2021
Abstract
BACKGROUND
Stroke is one of the major causes of disability and death worldwide. Some treatments for stroke exist, but existing treatment methods have limitations such as difficulty in the regeneration of damaged neuronal cells of the brain. Recently, mesenchymal stem cells (MSCs) have been studied as a therapeutic alternative for stroke, and various preclinical and case studies have been reported.
CASE SUMMARY
A 55-year-old man suffered an acute stroke, causing paralysis in the left upper and lower limbs. He intravenously transplanted the minimally manipulated human umbilical cord-derived MSCs (MM-UC-MSCs) twice with an 8-d interval. At 65 wk after transplantation, the patient returned to his previous occupation as a veterinarian with no adverse reactions.
CONCLUSION
MM-UC-MSCs transplantation potentially treats patients who suffer from acute ischemic stroke.
Core Tip: Previous results of preclinical and case studies showed the effectiveness of mesenchymal stem cells (MSCs) transplantation to stroke patients. In this case study, the patient who suffered from acute ischemic stroke was successfully treated using allogenic, minimally manipulated human umbilical cord-derived MSCs. This is the first report of using minimally manipulated human umbilical cord-derived MSCs to treat acute ischemic stroke.
